These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. Burshell AL, Möricke R, Correa-Rotter R, Chen P, Warner MR, Dalsky GP, Taylor KA, Krege JH. Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081 [Abstract] [Full Text] [Related]
8. Bone mineral density is not significantly reduced in adult patients on low-dose glucocorticoid replacement therapy. Koetz KR, Ventz M, Diederich S, Quinkler M. J Clin Endocrinol Metab; 2012 Jan; 97(1):85-92. PubMed ID: 21994966 [Abstract] [Full Text] [Related]
10. Circulating sclerostin levels and markers of bone turnover in Chinese-American and white women. Costa AG, Walker MD, Zhang CA, Cremers S, Dworakowski E, McMahon DJ, Liu G, Bilezikian JP. J Clin Endocrinol Metab; 2013 Dec; 98(12):4736-43. PubMed ID: 24037879 [Abstract] [Full Text] [Related]
11. Long-term follow-up of bone mineral density in Addison's disease. Jódar E, Valdepeñas MP, Martinez G, Jara A, Hawkins F. Clin Endocrinol (Oxf); 2003 May; 58(5):617-20. PubMed ID: 12699444 [Abstract] [Full Text] [Related]
12. Bone density and turnover in Addison's disease: effect of glucocorticoid treatment. Valero MA, Leon M, Ruiz Valdepeñas MP, Larrodera L, Lopez MB, Papapietro K, Jara A, Hawkins F. Bone Miner; 1994 Jul; 26(1):9-17. PubMed ID: 7950508 [Abstract] [Full Text] [Related]
13. Reference intervals for serum concentrations of three bone turnover markers for men and women. Michelsen J, Wallaschofski H, Friedrich N, Spielhagen C, Rettig R, Ittermann T, Nauck M, Hannemann A. Bone; 2013 Dec; 57(2):399-404. PubMed ID: 24076251 [Abstract] [Full Text] [Related]
14. The Relevance of Osteoclastic and Osteoblastic Activity Markers Follow-Up in Patients on Antiresorptive Osteoporosis Treatment. Smilic TN, Novakovic TR, Markovic-Jovanovic SR, Smilic LLJ, Mitic JS, Radunovic ML. J Clin Densitom; 2018 Dec; 21(3):322-328. PubMed ID: 29103946 [Abstract] [Full Text] [Related]
15. [Introduction: Patients with primary adrenal insufficiency receive long - term glucocorticoid replacement therapy, which may cause osteoporosis]. Vaňuga P, Ságová I. Vnitr Lek; 2021 Dec; 67(5):264-269. PubMed ID: 35459392 [Abstract] [Full Text] [Related]
16. Bone mineral density: serum markers of bone turnover and their relationships in peritoneal dialysis. Negri AL, Barone R, Quiroga MA, Bravo M, Marino A, Fradinger E, Bogado CE, Zanchetta JR. Perit Dial Int; 2004 Dec; 24(2):163-8. PubMed ID: 15119637 [Abstract] [Full Text] [Related]
17. Association of adiposity indices with bone density and bone turnover in the Chinese population. Wang J, Yan D, Hou X, Chen P, Sun Q, Bao Y, Hu C, Zhang Z, Jia W. Osteoporos Int; 2017 Sep; 28(9):2645-2652. PubMed ID: 28555285 [Abstract] [Full Text] [Related]
19. Serum sclerostin levels associated with lumbar spine bone mineral density and bone turnover markers in patients with postmenopausal osteoporosis. Xu XJ, Shen L, Yang YP, Lu FR, Zhu R, Shuai B, Li CG, Wu MX. Chin Med J (Engl); 2013 Jul; 126(13):2480-4. PubMed ID: 23823821 [Abstract] [Full Text] [Related]
20. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. Eastell R, Christiansen C, Grauer A, Kutilek S, Libanati C, McClung MR, Reid IR, Resch H, Siris E, Uebelhart D, Wang A, Weryha G, Cummings SR. J Bone Miner Res; 2011 Mar; 26(3):530-7. PubMed ID: 20839290 [Abstract] [Full Text] [Related] Page: [Next] [New Search]